Today's announcement about start of Phase 2b trial for OMS302 (for cataract surgery) seems to have done nothing in terms of share price... trading in relatively tight range on low volume. Somehow I guess the idea of another development 'project' that is long term, and entails only spending (vs. receiving) money for the foreseeable future isn't that compelling to investors!?
For positive SP movement, Omeros clearly needs news regarding either 1) positive P3 results for OMS103, and/or 2) partnership of just about ANY program with big pharma to help provide cash in the door and alleviate cash burn.
And I guess the downward drum beat is due to the fact that now, thanks to the Azimuth deal, we have a clear path to continued dilution.... but still no visibility into where revenue will come from. Even a BioBucks deal would be welcome at this juncture.